DuoTrav® Eye Drops As Replacement Therapy Program

This study has been completed.
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
First received: January 23, 2009
Last updated: September 18, 2012
Last verified: July 2012
To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).

Condition Intervention Phase
Open-angle Glaucoma
Ocular Hypertension
Drug: DuoTrav
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Intra Ocular Pressure [ Time Frame: visit 1, Visits 2-3, Visits 6-8 ] [ Designated as safety issue: No ]

Enrollment: 128
Study Start Date: February 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: DuoTrav
DuoTrav Eye Drops


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00828906

Contact Alcon for Trial Locations
Bejing, China
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00828906     History of Changes
Other Study ID Numbers: DART-2 
Study First Received: January 23, 2009
Last Updated: September 18, 2012
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Alcon Research:

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on May 22, 2016